- Home
- BIIB vs COO Comparison
BIIB vs COO Comparison
Compare BIIB & COO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- COO
- Stock Information
- Founded
- BIIB 1978
- COO 1980
- Country
- BIIB United States
- COO United States
- Employees
- BIIB 7605
- COO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- COO Ophthalmic Goods
- Sector
- BIIB Health Care
- COO Health Care
- Exchange
- BIIB Nasdaq
- COO Nasdaq
- Market Cap
- BIIB 18.8B
- COO 16.4B
- IPO Year
- BIIB 1991
- COO N/A
- Fundamental
- Price
- BIIB $131.20
- COO $68.28
- Analyst Decision
- BIIB Buy
- COO Buy
- Analyst Count
- BIIB 26
- COO 9
- Target Price
- BIIB $194.95
- COO $100.38
- AVG Volume (30 Days)
- BIIB 1.7M
- COO 2.3M
- Earning Date
- BIIB 05-01-2025
- COO 05-29-2025
- Dividend Yield
- BIIB N/A
- COO N/A
- EPS Growth
- BIIB 26.39
- COO 21.95
- EPS
- BIIB 10.12
- COO 2.07
- Revenue
- BIIB $9,816,400,000.00
- COO $3,988,200,000.00
- Revenue This Year
- BIIB N/A
- COO $6.74
- Revenue Next Year
- BIIB N/A
- COO $6.57
- P/E Ratio
- BIIB $12.83
- COO $32.99
- Revenue Growth
- BIIB 1.59
- COO 6.88
- 52 Week Low
- BIIB $110.04
- COO $65.95
- 52 Week High
- BIIB $238.00
- COO $112.38
- Technical
- Relative Strength Index (RSI)
- BIIB 59.82
- COO 25.74
- Support Level
- BIIB $123.97
- COO $79.22
- Resistance Level
- BIIB $132.94
- COO $80.78
- Average True Range (ATR)
- BIIB 3.49
- COO 1.97
- MACD
- BIIB 1.04
- COO -0.94
- Stochastic Oscillator
- BIIB 88.37
- COO 12.09
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About COO The Cooper Companies Inc.
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.